ATE192922T1 - Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden - Google Patents
Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschädenInfo
- Publication number
- ATE192922T1 ATE192922T1 AT95900491T AT95900491T ATE192922T1 AT E192922 T1 ATE192922 T1 AT E192922T1 AT 95900491 T AT95900491 T AT 95900491T AT 95900491 T AT95900491 T AT 95900491T AT E192922 T1 ATE192922 T1 AT E192922T1
- Authority
- AT
- Austria
- Prior art keywords
- reperfusion injury
- medicinal
- production
- nitrogen oxide
- protect against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14661093A | 1993-11-02 | 1993-11-02 | |
PCT/US1994/012510 WO1995012394A1 (en) | 1993-11-02 | 1994-10-31 | Use of nitric oxide releasing compounds as protective agents in ischemia reperfusion injury |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE192922T1 true ATE192922T1 (de) | 2000-06-15 |
Family
ID=22518169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95900491T ATE192922T1 (de) | 1993-11-02 | 1994-10-31 | Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden |
Country Status (12)
Country | Link |
---|---|
US (1) | US5789447A (de) |
EP (1) | EP0726768B1 (de) |
JP (1) | JPH09508097A (de) |
AT (1) | ATE192922T1 (de) |
AU (1) | AU704173B2 (de) |
CA (1) | CA2175467A1 (de) |
DE (1) | DE69424560T2 (de) |
DK (1) | DK0726768T3 (de) |
ES (1) | ES2149338T3 (de) |
GR (1) | GR3034099T3 (de) |
PT (1) | PT726768E (de) |
WO (1) | WO1995012394A1 (de) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6255277B1 (en) | 1993-09-17 | 2001-07-03 | Brigham And Women's Hospital | Localized use of nitric oxide-adducts to prevent internal tissue damage |
US6190704B1 (en) * | 1994-09-23 | 2001-02-20 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Regulation of wound healing by nitric oxide |
GB9423868D0 (en) * | 1994-11-25 | 1995-01-11 | Wellcome Found | Compounds for use in medicine |
US5726209A (en) * | 1995-06-07 | 1998-03-10 | Alliance Pharmaceutical Corp. | Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir |
AU720686B2 (en) * | 1996-04-05 | 2000-06-08 | General Hospital Corporation, The | Treatment of a hemoglobinopathy |
US6232434B1 (en) | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
US6656452B1 (en) * | 1997-10-21 | 2003-12-02 | The General Hospital Corporation | Use of inhaled NO as anti-inflammatory agent |
ATE277038T1 (de) | 1997-12-23 | 2004-10-15 | Amersham Health As | Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung |
US6103275A (en) * | 1998-06-10 | 2000-08-15 | Nitric Oxide Solutions | Systems and methods for topical treatment with nitric oxide |
US20040043068A1 (en) * | 1998-09-29 | 2004-03-04 | Eugene Tedeschi | Uses for medical devices having a lubricious, nitric oxide-releasing coating |
US20040151785A1 (en) * | 1998-10-06 | 2004-08-05 | Diamedica Inc. | Method for treating insulin resistance through hepatic nitric oxide |
CA2254645A1 (en) * | 1998-11-23 | 2000-05-23 | Pulmonox Medical Corporation | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
US20070086954A1 (en) * | 1998-11-23 | 2007-04-19 | Miller Christopher C | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
ES2147162B1 (es) | 1999-01-27 | 2001-03-16 | Lacer Sa | "s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias". |
FR2794647A1 (fr) * | 1999-06-11 | 2000-12-15 | Centre Nat Rech Scient | Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules |
US7135498B1 (en) | 1999-06-14 | 2006-11-14 | Henry Ford Health System | Nitric oxide donors for inducing neurogenesis |
HUP0202150A3 (en) * | 1999-06-14 | 2003-10-28 | Henry Ford Health System Detro | Use of nitric oxide donors for inducing neurogenesis |
US7516742B2 (en) * | 1999-11-24 | 2009-04-14 | Cardinal Health 207, Inc. | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing |
US6811965B2 (en) * | 2000-03-08 | 2004-11-02 | Yoram Vodovotz | Kidney perfusion solution containing nitric oxide donor, inhibitor of NOS2, glutathione, gluconate and methods of use |
US6270779B1 (en) | 2000-05-10 | 2001-08-07 | United States Of America | Nitric oxide-releasing metallic medical devices |
FR2812200B1 (fr) * | 2000-07-27 | 2003-01-03 | Oxykines Therapeutics | Composition contenant une proteine complexant le fer et un precurseur du metabolisme du monoxyde d'azote et/ou un donneur chimique de monoxyde d'azote ; et utilisations |
DE60136366D1 (de) * | 2000-08-11 | 2008-12-11 | David R Whitlock | Ammoniak-oxidierende bakterien enthaltende zusammensetzungen zur steigerung der stickoxidproduktion, stickoxid-vorläufer und verfahren zu deren verwendung |
US7122018B2 (en) * | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
US6432077B1 (en) * | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
EP1436018A1 (de) * | 2001-09-26 | 2004-07-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Stickoxid freisetzende beschichtete medizinprodukte und verfahren zu ihrer herstellung |
US6703046B2 (en) | 2001-10-04 | 2004-03-09 | Medtronic Ave Inc. | Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
GB0125222D0 (en) * | 2001-10-19 | 2001-12-12 | Barts & London Nhs Trust | Composition for the treatment of microbial infections |
EP1472021A4 (de) * | 2002-01-11 | 2008-04-16 | David R Whitlock | Ammoniak oxidierende bakterien enthaltende zusammensetzungen und verwendungsverfahren dafür |
US20040038947A1 (en) * | 2002-06-14 | 2004-02-26 | The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services | Method of treating ischemia/reperfusion injury with nitroxyl donors |
AU2003257624A1 (en) * | 2002-08-20 | 2004-03-11 | Terumo Kabushiki Kaisha | Medical instrument to be implanted in the body |
US6936639B2 (en) * | 2002-08-21 | 2005-08-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroxyl progenitors in the treatment of heart failure |
US7531133B2 (en) * | 2002-09-10 | 2009-05-12 | Pulmonox Technologies Corporation | Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma |
US20050009789A1 (en) * | 2003-05-13 | 2005-01-13 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Service | Cyclooxygenase inhibition with nitroxyl |
ES2294543T3 (es) | 2003-07-09 | 2008-04-01 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Heal | Uso de sales de nitrilo para el tratamiento de afecciones cardiovasculares. |
US20070148136A1 (en) * | 2003-09-26 | 2007-06-28 | Whitlock David R | Methods of using ammonia oxidizing bacteria |
US20080085329A1 (en) * | 2003-10-22 | 2008-04-10 | Fred Hutchinson Cancer Research Center, Inc. | Methods, Compositions and Devices for Inducing Stasis in Cells, Tissues, Organs, and Organisms |
US20050136125A1 (en) * | 2003-10-22 | 2005-06-23 | Roth Mark B. | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms |
CA2555591C (en) | 2004-02-09 | 2011-01-04 | Amulet Pharmaceuticals, Inc. | Nitric oxide-releasing polymers |
WO2005105171A1 (en) * | 2004-04-29 | 2005-11-10 | Cube Medical A/S | A balloon for use in angioplasty with an outer layer of nanofibers |
US8518457B2 (en) * | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
EP1755715A4 (de) | 2004-05-11 | 2010-03-24 | Sensormedics Corp | Intermittierende dosierung von stickoxidgas |
US7362274B1 (en) * | 2004-07-09 | 2008-04-22 | Huan-Cheng Lien | Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna |
US20070154570A1 (en) * | 2004-09-29 | 2007-07-05 | Miller Christopher C | Use of nitric oxide in the treatment and disinfection of biofilms |
AU2006236150A1 (en) * | 2005-04-20 | 2006-10-26 | Fred Hutchinson Cancer Research Center | Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms |
US8557300B2 (en) * | 2005-05-19 | 2013-10-15 | University Of Cincinnati | Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite |
EP3556401A1 (de) | 2005-05-27 | 2019-10-23 | The University of North Carolina at Chapel Hill | Stickoxidfreisetzende partikel für stickoxidtherapeutika und biomedizinische anwendungen |
WO2007002444A1 (en) * | 2005-06-23 | 2007-01-04 | Johns Hopkins University | Thiol-sensitive positive inotropes |
US20070116785A1 (en) * | 2005-11-18 | 2007-05-24 | Miller Christopher C | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant |
EP1968615A4 (de) * | 2005-12-06 | 2010-08-04 | Amulet Pharmaceuticals Inc | Stickoxid freisetzende polymere |
AU2014201936B2 (en) * | 2006-10-06 | 2016-07-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Prevention of tissue ischemia, related methods and compositions |
EP2695896B1 (de) | 2006-10-06 | 2018-08-22 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Prävention von Gewebeischämie, damit in Zusammenhang stehende Verfahren und Zusammensetzungen |
US8079998B2 (en) * | 2006-10-20 | 2011-12-20 | Pulmonox Technologies Corporation | Methods and devices for the delivery of therapeutic gases including nitric oxide |
EP1939179A1 (de) | 2006-12-28 | 2008-07-02 | Lacer, S.A. | Stabile S-Nitrosothiole, Syntheseverfahren und Verwendung |
WO2008089282A2 (en) * | 2007-01-16 | 2008-07-24 | Silver James H | Sensors for detecting subtances indicative of stroke, ischemia, infection or inflammation |
US20080193566A1 (en) * | 2007-02-09 | 2008-08-14 | Miller Christopher C | Use of high dose concentrations of gaseous nitric oxide |
US20080269109A1 (en) * | 2007-04-30 | 2008-10-30 | Becker Lance B | System and method of resuscitation of a mammal |
CA2710349A1 (en) * | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide -donating compounds and uses thereof |
BR112012003804B1 (pt) | 2009-08-21 | 2019-02-19 | Novan, Inc. | Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento |
WO2011022652A1 (en) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Topical gels |
WO2011063339A1 (en) * | 2009-11-23 | 2011-05-26 | Cardioxyl Pharmaceuticals, Inc. | Nitroxyl donors for the treatment of pulmonary hypertension |
CA2782248A1 (en) | 2009-12-07 | 2011-06-16 | Cardioxyl Pharmaceuticals, Inc. | Bis-acylated hydroxylamine derivatives |
CN105919987B (zh) * | 2009-12-07 | 2020-04-03 | 约翰斯霍普金斯大学 | N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物及其用途 |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
WO2012118829A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same |
WO2012154975A2 (en) * | 2011-05-11 | 2012-11-15 | Stc.Unm | Nitric oxide/cgmp pathway inhibition of vla-4 related cell adhesion |
US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
CA2880085C (en) | 2012-06-04 | 2021-09-07 | Diamedica Inc. | Human tissue kallikrein 1 glycosylation isoforms |
US8883857B2 (en) | 2012-12-07 | 2014-11-11 | Baylor College Of Medicine | Small molecule xanthine oxidase inhibitors and methods of use |
US11225640B2 (en) | 2014-04-15 | 2022-01-18 | Aobiome Llc | Ammonia oxidizing bacteria for treatment of psoriasis |
CA3207619A1 (en) | 2014-04-15 | 2015-10-22 | Aobiome Llc | Ammonia-oxidizing nitrosomonas eutropha strain d23 |
US10662063B1 (en) * | 2016-06-06 | 2020-05-26 | University Of Puerto Rico | Photosensitized release of nitric oxide |
WO2018067838A1 (en) | 2016-10-07 | 2018-04-12 | The University Of North Carolina At Chapel Hill | S-nitrosothiol-mediated hyperbranched polyesters |
WO2018127819A1 (en) | 2017-01-03 | 2018-07-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
EP3592377A4 (de) | 2017-03-09 | 2021-02-17 | Diamedica Inc. | Darreichungsformen von gewebekallikrein 1 |
CA3055474A1 (en) | 2017-03-28 | 2018-10-04 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto |
JP2021515083A (ja) | 2018-03-06 | 2021-06-17 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill | 生分解性の抗菌性足場としての一酸化窒素放出性シクロデキストリンおよびそれに関する方法 |
US11421044B2 (en) | 2018-12-28 | 2022-08-23 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3153094A (en) * | 1959-06-10 | 1964-10-13 | Du Pont | Nitrosamine manufacture |
US5039705A (en) * | 1989-09-15 | 1991-08-13 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
US5212204A (en) * | 1989-10-18 | 1993-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Antihypertensive compositions and use thereof |
US5155137A (en) * | 1990-09-20 | 1992-10-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Complexes of nitric oxide with polyamines |
US5714511A (en) * | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
-
1994
- 1994-10-31 JP JP7513345A patent/JPH09508097A/ja active Pending
- 1994-10-31 PT PT95900491T patent/PT726768E/pt unknown
- 1994-10-31 AU AU81300/94A patent/AU704173B2/en not_active Ceased
- 1994-10-31 DK DK95900491T patent/DK0726768T3/da active
- 1994-10-31 CA CA002175467A patent/CA2175467A1/en not_active Abandoned
- 1994-10-31 WO PCT/US1994/012510 patent/WO1995012394A1/en active IP Right Grant
- 1994-10-31 DE DE69424560T patent/DE69424560T2/de not_active Expired - Fee Related
- 1994-10-31 ES ES95900491T patent/ES2149338T3/es not_active Expired - Lifetime
- 1994-10-31 AT AT95900491T patent/ATE192922T1/de not_active IP Right Cessation
- 1994-10-31 EP EP95900491A patent/EP0726768B1/de not_active Expired - Lifetime
-
1995
- 1995-09-12 US US08/527,314 patent/US5789447A/en not_active Expired - Fee Related
-
2000
- 2000-08-02 GR GR20000401796T patent/GR3034099T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU8130094A (en) | 1995-05-23 |
US5789447A (en) | 1998-08-04 |
AU704173B2 (en) | 1999-04-15 |
GR3034099T3 (en) | 2000-11-30 |
DE69424560D1 (de) | 2000-06-21 |
PT726768E (pt) | 2000-11-30 |
EP0726768A1 (de) | 1996-08-21 |
DK0726768T3 (da) | 2000-10-02 |
DE69424560T2 (de) | 2001-01-18 |
WO1995012394A1 (en) | 1995-05-11 |
EP0726768B1 (de) | 2000-05-17 |
ES2149338T3 (es) | 2000-11-01 |
JPH09508097A (ja) | 1997-08-19 |
CA2175467A1 (en) | 1995-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE192922T1 (de) | Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden | |
ATE194769T1 (de) | Verwendung von stickstoffoxid freisetzenden verbindungen als arzneimittel zur strahlungssensibilisation fur hypoxische zellen | |
PT671910E (pt) | Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma | |
GEP20033140B (en) | Substituted Bicyclic Derivatives Useful as Anticancer Agents | |
IN172553B (de) | ||
DE69331643D1 (de) | Zwischenprodukte zur Herstellung retroviraler proteasehemmenden Verbindungen | |
ATE108657T1 (de) | Galanthemin enthaltende pharmazeutische formulierung zur behandlung des alkoholismus. | |
DE60234577D1 (de) | Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält | |
GEP20002298B (en) | Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment | |
SE8102193L (sv) | Terapeutiskt aktiv organisk forening och dess anvendning | |
ATE270553T1 (de) | Anwendung von 1,2,4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren | |
DE69327330D1 (de) | Verfahren zum bekämpfen der pneumocystis carinii pneumonie und dafür verwendbare verbindungen | |
DE3877647T2 (de) | Physiologisch wirksame produkte, verfahren zur herstellung und zusammensetzung. | |
DE69424777T2 (de) | 3,4-diarylchromane zur behandlung von dermatitis | |
DE3581416D1 (de) | Arzneimittel und die verwendung schwerloeslicher calcium- und/oder magnesiumverbindungen zur herstellung eines arzneimittels. | |
DE69111974T2 (de) | Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum. | |
MY104521A (en) | Treatment of depression. | |
ES2101100T3 (es) | Un producto para el tratamiento del cancer de higado y su procedimiento de manufactura. | |
ATE102955T1 (de) | Zyklisches tetrapeptid und verfahren zu dessen herstellung. | |
GB1511645A (en) | Sickle cell anaemia treatment | |
KR940000443A (ko) | 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드 | |
ATE170400T1 (de) | Verwendung von trovafloxacin oder dessen derivaten zur herstellung eines arzneimittels zur behandlung von h.pylori infektionen | |
DE69910706D1 (de) | Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie | |
DE69932741D1 (de) | Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen | |
ATE444755T1 (de) | Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |